Robin Deterding,^1,2 Lisa R Young,³ Emily M DeBoer,^1,2 David Warburton,^4,5 Steven Cunningham,⁶ Nicolaus Schwerk,⁷ Kevin R Flaherty,⁸ Kevin K Brown,⁹ Mihaela Dumistracel,¹⁰ Elvira Erhardt,¹¹ Julia Bertulis,¹¹ Martina Gahlemann,¹² Susanne Stowasser,¹³ Matthias Griese¹⁴ on behalf of the InPedILD trial investigators

¹Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, CO, USA; ²The Children’s Hospital Colorado, Aurora, CO, USA; ³Division of Pulmonary and Sleep Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ⁴Children’s Hospital Los Angeles, Los Angeles, CA, USA; ⁵Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁶Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; ⁷Clinic for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; ⁸Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA; ⁹Department of Medicine, National Jewish Health, Denver, CO, USA; ¹⁰Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; ¹¹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ¹²Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; ¹³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; ¹⁴Hauner Children’s Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Munich, Germany.

• Childhood ILD (chILD) is associated with significant morbidity and mortality.¹
• It was postulated that nintedanib would provide benefit in patients with clinically significant fibrosing chILD based on:
  • Similarities in pathophysiology of fibrotic lung remodelling in adults and children²
  • The mode of action of nintedanib, which inhibits processes fundamental to the progression of lung fibrosis³
  • The established clinical benefit of nintedanib in adults with fibrosing ILDs of diverse aetiology.^4-6